Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Annexin Pharmaceuticals

14.70 SEK

+1.38 %

Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Annexin Pharmaceuticals

2019202020212022202320242025
Revenue
growth-%
EBITDA-28.1-43.5-51.2-40.7-44.2-50.5-
EBIT-28.3-43.7-51.2-40.7-44.2-50.5-37.4
Profit before taxes-28.4-44.2-52.1-0.7-44.1-50.3-36.9
Net income-28.4-44.2-52.1-40.7-44.1-50.3-36.9
EPS-52.59-30.94-41.03-15.59-23.89-9.76-4.51
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%
EBIT-%
ROE-246.9 %-214.4 %-111.6 %-135.1 %-234.2 %-366.5 %-147.9 %
ROI-176.9 %-175.8 %-98.8 %-111.0 %-164.6 %-263.9 %-122.3 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.